The adult psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe population, which cannot be adequately controlled with conventional systemic and topical agents. The dominance of the TNF-alpha inhibitors, Amgen's PDE-4 inhibitor Otezla, and Janssen’s IL-12/23 inhibitor Stelara is now being challenged by the launch of highly effective IL-17 inhibitors—notably, Novartis’s Cosentyx and Eli Lilly’s Taltz—and IL-23 inhibitors—in particular, Janssen’s Tremfya and AbbVie's Skyrizi.

QUESTIONS ANSWERED

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed adult psoriasis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult psoriasis patients?
  • How have IL-17 inhibitors and IL-23 inhibitors been integrated into the treatment algorithm?
  • What proportion of adult psoriasis patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of adult psoriasis patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated adult patients with psoriasis?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

The Treatment Algorithms dashboard supplements our claims data analysis report and retains the full set of analyses included in the PowerPoint-based report. The interactive dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.

Table of contents

  • Psoriasis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Adult Psoriasis 2020 – Main Report Dashboard (US)

Author(s): Mohit Nasa, MBA

Mohit Nasa is a Lead Insights analyst on the Immune and Inflammatory team at Decision Resources Group and has authored content for indications like asthma and rheumatoid arthritis.

He holds a Bachelor’s degree in Pharmacy and has earned his MBA in marketing and CRM from Amity Business School. Prior to joining DRG, Mohit worked as a Senior Business analyst at Novartis where he was responsible for end to end market assessment, reporting analytics and related projects for Novartis’s asthma brand Xolair. Mohit has also worked as Brand Manager at Ozone pharma and an Account Manager for IMS Health.


Related Reports

Psoriasis - Landscape & Forecast - Disease Landscape & Forecast

The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue...

View Details

Psoriasis - Access & Reimbursement - Detailed, Expanded Analysis (US)

This report is available to find out more click the link and fill out the form to get more details.

View Details

Psoriasis - Current Treatment - Detailed, Expanded Analysis (EU5)

Multiple treatment options

View Details

Psoriasis - Geographic Focus: China - Psoriasis|China In-Depth|China

Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the gro...

View Details